Research programme: schizophrenia therapeutic - QLT USAAlternative Names: Atrigel® risperidone; Risperidone implant - QLT USA; Sustained release risperidone - QLT USA
Latest Information Update: 11 Nov 2009
At a glance
- Originator QLT USA
- Class Pyrimidinones
- Mechanism of Action Dopamine D2 receptor antagonists; Serotonin 2 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Schizophrenia
Most Recent Events
- 22 Nov 2004 Atrix Laboratories has been acquired by QLT
- 11 Aug 2004 Preclinical trials in Schizophrenia in USA (Injection)